The anti-CD137 agonist urelumab can overcome transforming growth factor (TGF)-β-mediated inhibition of human NK-cell proliferation and anti-tumor function and preserve the expressions of NKG2D, granzyme B, and interferon-gamma (IFN-γ) in HER2-positive primary breast cancer (60). This evidence concerns the gene ERBB2 and breast carcinoma.